Skip to main content

Peer Review reports

From: Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)

Original Submission
4 Feb 2021 Submitted Original manuscript
10 Jul 2021 Reviewed Reviewer Report
13 Jul 2021 Reviewed Reviewer Report
16 Jul 2021 Reviewed Reviewer Report
24 Aug 2021 Author responded Author comments - Bo Zhang
Resubmission - Version 2
24 Aug 2021 Submitted Manuscript version 2
10 Oct 2021 Reviewed Reviewer Report
11 Nov 2021 Reviewed Reviewer Report
26 Dec 2021 Author responded Author comments - Bo Zhang
Resubmission - Version 3
26 Dec 2021 Submitted Manuscript version 3
2 Feb 2022 Reviewed Reviewer Report
2 Feb 2022 Reviewed Reviewer Report
25 Feb 2022 Author responded Author comments - Bo Zhang
Resubmission - Version 4
25 Feb 2022 Submitted Manuscript version 4
7 Mar 2022 Author responded Author comments - Bo Zhang
Resubmission - Version 5
7 Mar 2022 Submitted Manuscript version 5
10 Mar 2022 Author responded Author comments - Bo Zhang
Resubmission - Version 6
10 Mar 2022 Submitted Manuscript version 6
Publishing
11 Mar 2022 Editorially accepted
19 Mar 2022 Article published 10.1186/s12885-022-09409-3

You can find further information about peer review here.

Back to article page